In the past week, there have been a number of stocks that have managed to clock significant gains and one of those is Northwest Biotherapeutics (OTCMKTS:NWBO), which clocked gains of 11% during the period.
Trading Data
On Monday, NWBO stock moved up 0.18% to $0.7095 with more than 3.74 million shares, compared to its average volume of 1.69 million shares. The stock moved within a range of $0.6722 – 0.7788 after opening trade at $0.7200.
Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA
The company is currently best known for its work on the development of DCVax, a customized immune therapy for treating solid cancer tumors. Last week on August 23, Northwest was in the news after it announced that its Pediatric Investigation Plan had won the approval of the UK Medicines and Healthcare Products Regulatory Agency. It was a major new development for Northwest and the rally in the stock is perhaps understandable.
The approval of the Pediatric Investigation Plan is a significant milestone for the company since it is a precondition for sending in applications for the approval of medicines like DCVax for adults. The approved Pediatric Investigation Plan is going to consist of as many as two clinical trials. It was further announced that in both pediatric trials as many as 24 patients are going to be treated with DCVax. In the United Kingdom, if a new medicine is developed for adults, then it must also be checked for potentially treating pediatric patients.
Technical Data
NWBO stock is trading above the 20-Day and 50-Day Moving averages of $0.67 and $0.68 respectively. However, the stock is trading below the 200-Day moving average of $0.80. The company has a total market capitalization of $698 million.
